Clinical Trial Update: Sorafenib and Dacarbazine in Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of sorafenib and dacarbazine in soft tissue sarcoma reported completed results in 2015, including synovial sarcoma, l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Malignant Peripheral Nerve Sheath Tumor
• Soft Tissue Sarcoma
• Synovial Sarcoma

Drugs mentioned

• DTIC-Dome (dacarbazine)
• Nexavar (Sorafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma, Synovial Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-11-20